<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04411836</url>
  </required_header>
  <id_info>
    <org_study_id>EFFORT</org_study_id>
    <nct_id>NCT04411836</nct_id>
  </id_info>
  <brief_title>Effectiveness of Novel Approaches to Radical Cure With Tafenoquine and Primaquine</brief_title>
  <acronym>EFFORT</acronym>
  <official_title>Effectiveness of Novel Approaches to Radical Cure With Tafenoquine and Primaquine - a Randomized Controlled Trial in P. Vivax Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Menzies School of Health Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Melbourne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Centre for Parasitology, Entomology and Malaria Control, Cambodia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mahidol Oxford Tropical Medicine Research Unit</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Addis Ababa University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ethiopian Public Health Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universitas Sumatera Utara</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Menzies School of Health Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Health care facility based, randomized, controlled, open label, superiority trial with 3 arms&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  To assess the effectiveness of a short-course of high dose primaquine (total dose 7mg/kg&#xD;
           given unsupervised over 7 days) compared to the current standard low dose primaquine&#xD;
           regimen (total dose 3.5mg/kg given unsupervised over 14 days).&#xD;
&#xD;
        -  To assess the effectiveness of tafenoquine (single dose of 300mg) compared to the&#xD;
           short-course high dose primaquine regimen.&#xD;
&#xD;
        -  To assess the safety of tafenoquine compared to the high and low dose primaquine&#xD;
           regimens.&#xD;
&#xD;
        -  To assess the cost-effectiveness and feasibility of high dose primaquine and tafenoquine&#xD;
           compared to the current low dose primaquine regimen&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 25, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence risk symptomatic P vivax PQ7 / PQ14</measure>
    <time_frame>6 months</time_frame>
    <description>The incidence risk (time to first event) of symptomatic P. vivax parasitaemia during the 6-month follow up period as determined by microscopy compared between the PQ7 arm and the control arm (PQ14).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence risk symptomatic P vivax PQ7 / TQ</measure>
    <time_frame>6 months</time_frame>
    <description>The incidence risk (time to first event) of symptomatic P. vivax parasitaemia during the 6 months follow up period as determined by microscopy compared between PQ7 and TQ arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence risk symptomatic P vivax TQ / PQ14</measure>
    <time_frame>6 months</time_frame>
    <description>The incidence risk (time to first event) of symptomatic P. vivax parasitaemia during the 6 months follow up period as determined by microscopy compared between TQ and the control arm (PQ14).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence risk any P vivax PQ7 / PQ14</measure>
    <time_frame>6 months</time_frame>
    <description>The incidence risk (time to first event) of any P. vivax parasitaemia during the 6-month follow up period as determined by microscopy compared between the PQ7 arm and the control arm (PQ14).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence risk any P vivax PQ7 / TQ</measure>
    <time_frame>6 months</time_frame>
    <description>• The incidence risk (time to first event) of any P. vivax parasitaemia during the 6 months follow up period as determined by microscopy compared between PQ7 and TQ arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence risk any P vivax PQ14 / TQ</measure>
    <time_frame>6 months</time_frame>
    <description>The incidence risk (time to first event) of any P. vivax parasitaemia during the 6 months follow up period as determined by microscopy compared between PQ14 and TQ arms</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">720</enrollment>
  <condition>Vivax Malaria</condition>
  <condition>Plasmodium Vivax</condition>
  <condition>Malaria, Vivax</condition>
  <condition>Malaria Relapse</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients are treated with schizontocidal treatment plus low dose PQ (total dose 3.5mg/kg) unsupervised over 14 days (PQ14)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PQ Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are treated with schizontocidal treatment plus high dose PQ (total dose 7 mg/kg) unsupervised over 7 days (PQ7)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TQ Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are treated with schizontocidal treatment plus a single dose of Tafenoquine (TQ)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tafenoquine</intervention_name>
    <description>patients are treated with schizontocidal treatment plus a single dose of Tafenoquine (TQ).</description>
    <arm_group_label>TQ Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Primaquine</intervention_name>
    <description>patients are treated with schizontocidal treatment plus high dose PQ (total dose 7 mg/kg) unsupervised over 7 days (PQ7)</description>
    <arm_group_label>PQ Intervention</arm_group_label>
    <other_name>Primaquine 7 days</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  P. vivax peripheral parasitaemia (mono-infection) as determined by microscopy&#xD;
&#xD;
          -  G6PD normal status (G6PD activity ≥ 70% of the adjusted male median as determined by&#xD;
             the Biosensor™ (SD Biosensor, ROK))&#xD;
&#xD;
          -  Fever (temperature ≥37.5⁰C) or history of fever in the preceding 48 hours&#xD;
&#xD;
          -  Age ≥18 years&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Living in the study area and willing to be followed for six months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Danger signs or symptoms of severe malaria&#xD;
&#xD;
          -  Anaemia (defined as Hb &lt;8g/dl)&#xD;
&#xD;
          -  Pregnant or lactating females&#xD;
&#xD;
          -  Known hypersensitivity to any of the study drugs&#xD;
&#xD;
          -  Regular use of drugs with haemolytic potential&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kamala Thriemer, MD, MPH, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Menzies School of Health Research</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kamala Thriemer, MD, MPH, PhD</last_name>
    <phone>0889468644</phone>
    <email>kamala.ley-thriemer@menzies.edu.au</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kravanh District Hospital</name>
      <address>
        <city>Pursat</city>
        <state>Pursat Province</state>
        <country>Cambodia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rupam Tripura, MD</last_name>
    </contact>
    <investigator>
      <last_name>Lorenz von Seidlein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lek Dysoley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rupam Tripura, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tom Peto, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>James Callery, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Siem Pang Health Centre</name>
      <address>
        <city>Stung Treng</city>
        <country>Cambodia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arba Minch General Hospital</name>
      <address>
        <city>Arba Minch</city>
        <country>Ethiopia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tamiru Shibiru Degaga, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tanjung Leidong Health Center</name>
      <address>
        <city>Labuhanbatu</city>
        <state>Sumatera</state>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ayodhia Pasaribu Pitaloka, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Cambodia</country>
    <country>Ethiopia</country>
    <country>Indonesia</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 28, 2020</study_first_submitted>
  <study_first_submitted_qc>May 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 2, 2020</study_first_posted>
  <last_update_submitted>May 31, 2021</last_update_submitted>
  <last_update_submitted_qc>May 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>tafenoquine</keyword>
  <keyword>primaquine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
    <mesh_term>Malaria, Vivax</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Primaquine</mesh_term>
    <mesh_term>Tafenoquine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Study Protocol and Statistical Analysis Plan will be made available to others. Data collected for the study, including individual patient data and the final trial dataset are reserved for the chief investigator and co-investigators of the trial. The trial will be reported in accordance with the Consolidated Standards of Reporting Trials (CONSORT) guidelines. Trial results will be published in peer-reviewed open access journals and disseminated to trial stakeholders, including participants, as per ethical guidelines.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_access_criteria>The data are available for access via the WorldWide Antimalarial Resistance Network (WWARN.org). Requests for access will be reviewed by a Data Access Committee to ensure that use of data protects the interests of the participants and researchers according to the terms of ethics approval and principles of equitable data sharing. Requests can be submitted by email to malariaDAC@iddo.org via the Data Access Form available at WWARN.org/accessing-data. The WWARN is registered with the Registry of Research Data Repositories (re3data.org).</ipd_access_criteria>
    <ipd_url>http://WWARN.org/accessing-data</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

